Curida and the Norwegian Armed Forces enter into a contingency agreement.

Published: 16 Nov 2017

On Tuesday November 14th, Curida signed a letter of intent with the Norwegian Armed Forces on raw materials supply and pharmaceutical manufacturing in emergency preparedness. The agreement was signed by Managing Director of the Armed Forces Logistics Organization, Petter Jansen, and Curida’s CEO, Leif Rune Skymoen during a conference on logistics preparedness in Narvik, northern Norway.
This agreement is part of a larger strategic effort by the Armed Forces to build a sustainable emergency response in alliance with partners from the private sector to guarantee flexible access to goods and services while optimizing costs. Curida’s role is to ensure the production of medications during crisis, war and other conflicts and will participate actively in the planning, coordination and simulations during peacetime so that resources become available when the need arises.

Curida is a Norwegian pharmaceutical company with manufacturing facilities in Elverum. The company was founded in 2015, after an employee and management buy-out of a Takeda site which had been active in various outfits since 1974. The company specializes in contract development and manufacturing of sterile liquid medications for international pharmaceutical companies.

Both parties will now start to settle the details of the final agreement, which is expected to last between 4 to 9 years.

“We expect that Curida will play a key role in drug preparedness, and there are significant development opportunities during the contract period. This is an important agreement for the Armed Forces,” says Petter Jansen.
– Pharmaceutical manufacturing is important for Norway from both a business perspective and in terms of civil and military preparedness. We are pleased that our expertise will benefit society and the people, “says Leif Rune Skymoen.